NO20022711L - Fremgangsmåte for testing av et terapeutisk eller profylaktisk middel for hyperlipidemi - Google Patents

Fremgangsmåte for testing av et terapeutisk eller profylaktisk middel for hyperlipidemi

Info

Publication number
NO20022711L
NO20022711L NO20022711A NO20022711A NO20022711L NO 20022711 L NO20022711 L NO 20022711L NO 20022711 A NO20022711 A NO 20022711A NO 20022711 A NO20022711 A NO 20022711A NO 20022711 L NO20022711 L NO 20022711L
Authority
NO
Norway
Prior art keywords
hyperlipidemia
testing
therapeutic
prophylactic agent
prophylactic
Prior art date
Application number
NO20022711A
Other languages
English (en)
Other versions
NO20022711D0 (no
Inventor
Ryuta Koishi
Mitsuru Ono
Hidehiko Furukawa
Hiroyoshi Horikoshi
Toshihiko Fujiwara
Yosuke Ando
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of NO20022711D0 publication Critical patent/NO20022711D0/no
Publication of NO20022711L publication Critical patent/NO20022711L/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5067—Liver cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Ny fremgangsmåte for testing av et terapeutisk middel eller et profylaktisk middel for hyperlipidemi, og nukleinsyreprobe, primer og antistoff som anvendes ved fremgangsmåten. Nærmere bestemt fremgangsmåte for testing av virkningen av et prøvestoff som terapeutisk middel eller profylaktisk middel for hyperlipidemi, ved å anvende ekspresjonen av et gen representert ved SEQ ID No. 1 eller 2 i sekvenslisten, som deltar i kontrollen av nøytralfettnivået i blodet hos pattedyr, som en indikasjon, og nukleinsyreprobe, primer og antistoff som anvendes ved denne fremgangsmåten. Ved å anvende denne fremgangsmåten kan det letes etter kandi-dater til profylaktiske eller terapeut-iske midler for hyperlipidemi.
NO20022711A 1999-12-09 2002-06-07 Fremgangsmåte for testing av et terapeutisk eller profylaktisk middel for hyperlipidemi NO20022711L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP34997699 1999-12-09
PCT/JP2000/008722 WO2001042499A1 (en) 1999-12-09 2000-12-08 Method of testing remedy or preventive for hyperlipemia

Publications (2)

Publication Number Publication Date
NO20022711D0 NO20022711D0 (no) 2002-06-07
NO20022711L true NO20022711L (no) 2002-08-08

Family

ID=18407394

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20022711A NO20022711L (no) 1999-12-09 2002-06-07 Fremgangsmåte for testing av et terapeutisk eller profylaktisk middel for hyperlipidemi

Country Status (17)

Country Link
US (3) US20030017488A1 (no)
EP (1) EP1239050A4 (no)
KR (1) KR20020062652A (no)
CN (1) CN1433482A (no)
AU (1) AU768034B2 (no)
BR (1) BR0016257A (no)
CA (1) CA2390676A1 (no)
CZ (1) CZ20021853A3 (no)
HK (1) HK1045541A1 (no)
HU (1) HUP0203408A3 (no)
IL (1) IL149849A0 (no)
MX (1) MXPA02005758A (no)
NO (1) NO20022711L (no)
PL (1) PL355666A1 (no)
RU (1) RU2002115295A (no)
WO (1) WO2001042499A1 (no)
ZA (1) ZA200204432B (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002036808A2 (en) * 2000-11-03 2002-05-10 Diadexus, Inc. Compositions and methods relating to prostate specific genes and proteins
IL159153A0 (en) * 2001-06-08 2004-06-01 Sankyo Co Methods for testing drugs for treating or preventing diseases such as hyperlipidemia
JPWO2003028445A1 (ja) * 2001-08-31 2005-01-13 大塚製薬株式会社 Ｔｓａ２３０６遺伝子欠損非ヒト動物
WO2008073300A2 (en) 2006-12-08 2008-06-19 Lexicon Pharmaceuticals, Inc. Monoclonal antibodies against angptl3
US8143600B2 (en) * 2008-02-18 2012-03-27 Visiongate, Inc. 3D imaging of live cells with ultraviolet radiation
CN102753186B (zh) 2010-01-08 2016-09-14 Isis制药公司 血管生成素样3表达的调节
DK2992098T3 (da) 2013-05-01 2019-06-17 Ionis Pharmaceuticals Inc Sammensætninger og fremgangsmåder til modulering af hbv- og ttr-ekspression
PT3087183T (pt) 2013-12-24 2020-10-08 Ionis Pharmaceuticals Inc Modulação da expressão da proteína relacionada com angiopoietina 3
US9382540B2 (en) 2014-05-01 2016-07-05 Isis Pharmaceuticals, Inc Compositions and methods for modulating angiopoietin-like 3 expression
KR20250078597A (ko) 2015-11-06 2025-06-02 아이오니스 파마수티컬즈, 인코포레이티드 아포리포프로테인 (a) 발현 조정
TN2020000038A1 (en) 2017-09-14 2021-10-04 Arrowhead Pharmaceuticals Inc Rnai agents and compositions for inhibiting expression of angiopoietin-like 3 (angptl3), and methods of use
CN109806632A (zh) * 2019-03-01 2019-05-28 中国科学院武汉物理与数学研究所 一种全血过滤装置

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6030831A (en) * 1997-09-19 2000-02-29 Genetech, Inc. Tie ligand homologues
AU3661199A (en) * 1998-04-27 1999-11-16 Zymogenetics Inc. Novel polypeptide growth factors and materials and methods for making them
EP1078046A4 (en) * 1998-05-12 2005-05-11 Human Genome Sciences Inc 97 HUMAN SECRETED PROTEINS
SV1999000069A (es) * 1998-06-02 2000-04-11 Lilly Co Eli Angiopoyetina relacionada con secuencia del gen 3 en la cicatrizacion de la cara ref. x-12261
AU4643699A (en) * 1998-06-24 2000-01-10 Compugen Ltd. Angiopoietin-like growth factor sequences
AU1181900A (en) * 1998-11-17 2000-06-05 Protegene Inc. Human proteins having hydrophobic domains and dnas encoding these proteins
JP3695642B2 (ja) * 1998-12-01 2005-09-14 ジェネンテック・インコーポレーテッド 血管形成及び心臓血管新生の促進又は阻害
ES2327785T3 (es) * 1998-12-22 2009-11-03 Genentech, Inc. Procedimientos y compuestos para inhibir el crecimiento de celulas neoplasticas.
US20020015950A1 (en) * 1999-07-07 2002-02-07 Karen Anne Jones Atherosclerosis-associated genes
US20020054871A1 (en) * 1999-04-12 2002-05-09 Yadong Huang Methods and compositions for use in the treatment of hyperlipidemia
JP2000325087A (ja) * 1999-05-21 2000-11-28 Otsuka Pharmaceut Co Ltd Ｔｓａ２３０６遺伝子
EP1210363A2 (en) * 1999-07-16 2002-06-05 Hyseq, Inc. Novel angiopoietin materials and methods
EP1198568B1 (en) * 1999-07-20 2007-07-25 Genentech, Inc. Compositions and methods for the treatment of immune related diseases

Also Published As

Publication number Publication date
AU1887001A (en) 2001-06-18
CN1433482A (zh) 2003-07-30
HK1045541A1 (en) 2002-11-29
NO20022711D0 (no) 2002-06-07
EP1239050A1 (en) 2002-09-11
CZ20021853A3 (cs) 2002-11-13
ZA200204432B (en) 2003-09-29
WO2001042499A1 (en) 2001-06-14
HUP0203408A2 (hu) 2003-01-28
US20030211533A1 (en) 2003-11-13
HUP0203408A3 (en) 2005-01-28
AU768034B2 (en) 2003-11-27
US20030017488A1 (en) 2003-01-23
IL149849A0 (en) 2002-11-10
US20030207251A1 (en) 2003-11-06
CA2390676A1 (en) 2001-06-14
KR20020062652A (ko) 2002-07-26
MXPA02005758A (es) 2002-09-18
RU2002115295A (ru) 2004-01-10
EP1239050A4 (en) 2004-07-21
BR0016257A (pt) 2002-08-20
PL355666A1 (en) 2004-05-04

Similar Documents

Publication Publication Date Title
Lam et al. Editing of ubiquitin conjugates by an isopeptidase in the 26S proteasome
Dewar et al. CRL2Lrr1 promotes unloading of the vertebrate replisome from chromatin during replication termination
Stadtman Protein modification in aging
NO20022711L (no) Fremgangsmåte for testing av et terapeutisk eller profylaktisk middel for hyperlipidemi
EP0621284A4 (en) PEPTIDES CONTAINING SELECTED RESPECTIVE AMINO ACID SELECTED FROM LIPOPROTEIN (a) AND APOLIPOPROTEIN (a), ANTIBODIES RECOGNIZING THESE AMINO ACID SEQUENCES AND ANALYSIS METHOD USING THE SAME.
MY104957A (en) Method detecting nucleotide sequences.
DK1187591T3 (da) IBD-associerede mikrobielle antigener og fremgangsmåder til at anvende samme
WO2001012662A3 (en) Membrane associated proteins
DK104093D0 (da) Fremgangsmaade til bestemmelse af collagen-fragmenter i legemsvaesker, test-kit og midler til udoevelse af fremgangsmaaden og anvendelse af fremgangsmaaden til diagnosticering af lidelser associeret til collagen-metabolismen
Blagotinsek et al. An ATP-dependent partner switch links flagellar C-ring assembly with gene expression
NO881670L (no) Diagnostisk proeve paa inhibitor for plasminogenaktivatorerav vev- og urokinasetype, samt gen som koder for inhibitoren.
Burgos et al. Analysis of the activation process of porcine procarboxypeptidase B and determination of the sequence of its activation segment
DK0696642T3 (da) Fremgangsmåde til påvisning af forstyrrelser i protein C/protein S-systemet
EE200100040A (et) Meetod raku fenotüüpi muutva modulaatori identifitseerimiseks ja valmistamiseks, sihtmärkbiomolekulide eraldamiseks ja/või samastamiseks ning meditsiinitoote arendamiseks ja valmistamiseks
DK328584A (da) Immunobestemmelsesmetode for en iodthyronin i en biologisk vaeske samt reagenssystem, testsaet og testmateriale til anvendelse ved metoden
DE60038363D1 (de) Detektion von kleinen molekülen mit piezo-elektrischem sensor
NO970518L (no) Probe-system som tillater HLA-DR-typing samt fremgangsmåte ved anvendelse av slike prober
NO20006153L (no) Poly(ADP-ribose)polymerase gen
Stefanovics et al. Novel chymotrypsin C (CTRC) variants from real-world genetic testing of pediatric chronic pancreatitis cases
DE69913325D1 (de) Nephrin gen und protein
DE69840268D1 (de) Biologisches testverfahren für thyroid stimulierende antikörper
WO2001044448A3 (en) Human oxidoreductase proteins
AU2002257284A1 (en) Pna probes, probe sets, methods and kits pertaining to the detection of candida
Kivlen et al. Asymmetric distribution of pause transfer sequences in apolipoprotein B-100
EP0331514A3 (en) Assaying the duchenne muscular dystrophy protein deletion or defect

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application